Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Retained Earnings (2023 - 2025)

CG Oncology filings provide 3 years of Retained Earnings readings, the most recent being -$379.0 million for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 73.87% to -$379.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$379.0 million, a 73.87% decrease, with the full-year FY2025 number at -$379.0 million, down 73.87% from a year prior.
  • Retained Earnings hit -$379.0 million in Q4 2025 for CG Oncology, down from -$337.7 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$129.9 million in Q4 2023 to a low of -$379.0 million in Q4 2025.
  • Median Retained Earnings over the past 3 years was -$218.0 million (2024), compared with a mean of -$234.4 million.
  • Biggest five-year swings in Retained Earnings: plummeted 67.75% in 2024 and later plummeted 81.38% in 2025.
  • CG Oncology's Retained Earnings stood at -$129.9 million in 2023, then plummeted by 67.75% to -$218.0 million in 2024, then plummeted by 73.87% to -$379.0 million in 2025.
  • The last three reported values for Retained Earnings were -$379.0 million (Q4 2025), -$337.7 million (Q3 2025), and -$293.9 million (Q2 2025) per Business Quant data.